Wordt geladen...
Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib
Approximately 40% of chronic myeloid leukemia (CML) patients who discontinue imatinib (IM) therapy maintain undetectable minimal residual disease (UMRD) for more than one year (stopping IM (STOP-IM)). To determine a possible biomarker for STOP-IM CML, we examined plasma miRNA expression in CML patie...
Bewaard in:
Gepubliceerd in: | Int J Mol Sci |
---|---|
Hoofdauteurs: | , , , , , , , , |
Formaat: | Artigo |
Taal: | Inglês |
Gepubliceerd in: |
MDPI
2016
|
Onderwerpen: | |
Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4849026/ https://ncbi.nlm.nih.gov/pubmed/27092489 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms17040570 |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|